Crossmark

The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations

Crossref DOI link: https://doi.org/10.1038/s41409-025-02765-1

Published Online: 2025-12-23

Published Print: 2026-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Abou Dalle, Iman https://orcid.org/0000-0002-6520-9134
Galimard, Jacques-Emmanuel https://orcid.org/0000-0001-9102-4427
Poire, Xavier https://orcid.org/0000-0003-1897-0227
Sanz, Jaime https://orcid.org/0000-0001-6934-4619
Huynh, Anne

Kröger, Nicolaus

Wagner-Drouet, Eva Maria https://orcid.org/0000-0002-0728-2253
Burns, David

Eder, Matthias

Lioure, Bruno

Wu, Depei

Mayer, Jiri

Carlson, Kristina

Stelljes, Matthias https://orcid.org/0000-0002-9331-5145
Collin, Matthew

Aljurf, Mahmoud

Nagler, Arnon

Esteve, Jordi https://orcid.org/0000-0002-8056-648X
Ciceri, Fabio

Bazarbachi, Ali https://orcid.org/0000-0002-7171-4997
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
License Information

Text and Data Mining valid from 2025-12-23

Version of Record valid from 2025-12-23
More Information

Article History

Received: 25 June 2025

Accepted: 11 November 2025

First Online: 23 December 2025

Competing interests

: The authors declare no competing interests.

: The EBMT is a voluntary working group of more than 600 transplant centers that are required to report all consecutive HCTs and follow-ups once a year. Audits are routinely performed to determine the accuracy of the data. Since January 2003, all transplant centers have been required to obtain written informed consent before data registration with the EBMT, following the guidelines of the Declaration of Helsinki, 1975.

Document is current

Any future updates will be listed below